A successful Elocta bid means increased access to efmoroctocog alfa for all people with haemophilia A in the UK.
Through an agreement with the NHS and SobiTM UK, people living with haemophilia A in the United Kingdom will have increased access to efmoroctocog alfa following a successful bid in the United Kingdom’s Haemophilia A Tender.
Efmoroctocog alfa is licensed by the European Commission in all age groups for treatment and prophylaxis (prevention) of bleeding in patients with haemophilia A. It is an extended half-life (EHL) therapy reimbursed by NHS England and as well, suitable for all age ranges and all severities.
Previously many people living with haemophilia A in the UK had restricted access to efmoroctocog alfa with a finite volume available under the previous agreement. The new agreement is an important step forward for haemophilia A treatment, allowing physicians to prescribe the most suitable therapies and tailor approaches for patients to protect against bleeds and joint damage.
Treatment guidelines recently published by the British Society for Haemotology recommend that prophylactic treatment should be tailored to suit individual daily activity. EHL therapies have the potential to reduce injection frequency, increase treatment adherence, improve outcomes and potentially allow for a more active lifestyle.
The new framework agreement will commence on 1 July 2020 and will be operational for two years, with an option to extend for a further 24 months.
“This is exciting news for the haemophilia community in the UK. From July 1st everyone living with Haemophilia A of all ages and all severities will have access to efmoroctocog alfa,” said Simon Cox, Interim General Manager Sobi UK.
“We hope that with previous volume restrictions lifted, clinicians will have the confidence to prescribe efmoroctocog alfa whenever they feel appropriate, and in turn more people living with haemophilia A will be able to determine how they want to live their lives, aligned to our Liberate Life vision.” continued Simon.